ADB-FUBHQUCA is a synthetic cannabinoid receptor agonist that has been sold as a designer drug, first reported in 2022. It is related to the previously reported compound ADB-FUBICA but with the central indole ring system expanded to a 1,4-dihydroquinoline structure. This breaks the aromaticity of the ring system, and ADB-FUBHQUCA is relatively low in potency compared to related compounds where the aromatic core is retained.